AG
MNTA

Artal Group’s Momenta Pharmaceuticals, Inc. MNTA Stock Holding History

Artal Group’s Portfolio MNTA Stock Details MNTA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-200,000
Closed -$2.21M – 121
2018
Q4 		$2.21M Buy
+200,000
New +$2.78M 0.08% 93

Other funds holding MNTA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Artal Group's MNTA Position: Q1 2019 in Review

Artal Group sold out of Momenta Pharmaceuticals, Inc. (MNTA) in Q1 2019, closing a stake of 200,000 shares — an estimated $2.21M sold.

Artal Group first reported a position in MNTA in Q4 2018 and held it in 1 quarter. The position peaked at $2.21M in Q4 2018. 147 funds tracked by Wall St. Rank hold MNTA as of Q1 2019.

  • Artal Group reported no remaining Momenta Pharmaceuticals, Inc. position as of Q1 2019 after selling out during the quarter.
  • Artal Group sold 200,000 Momenta Pharmaceuticals, Inc. shares in Q1 2019, an estimated $2.21M.
  • Artal Group first reported a position in Momenta Pharmaceuticals, Inc. in Q4 2018 and held it in 1 quarter.
  • Artal Group's Momenta Pharmaceuticals, Inc. position peaked at $2.21M in Q4 2018.
  • 147 funds tracked by Wall St. Rank held Momenta Pharmaceuticals, Inc. as of Q1 2019.

Based on Artal Group's 13F filing for Q1 2019, filed 10 May 2019.